Cover Image


SLIT Tablets, Self-Administration, and Allergy Immunotherapy to 2022 - Products, Players, Markets, and Forecasts

出版商 Greystone Research Associates 商品編碼 324586
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
SLIT片劑、自我施打及過敏免疫療法:產品、企業、市場、預測 SLIT Tablets, Self-Administration, and Allergy Immunotherapy to 2022 - Products, Players, Markets, and Forecasts
出版日期: 2015年02月17日 內容資訊: 英文




  • 競爭情形
  • 過敏免疫療法市場
  • 過敏市場區分
  • 花粉型過敏
  • 過敏疾病中空氣污染的影響的可能性
  • 鄴扁虱
  • 寵物過敏
  • 食品過敏
  • 治療市場區分
  • 參加試驗的患者醫藥品
  • 處方藥
  • 新的治療區分
  • 合成肽表位
  • 淋巴管轄範圍內給藥 (ILIT給藥)
  • 經皮給藥
  • 下一代AIT
  • 重組的過敏原
  • 過敏治療技術的平台
  • 連續重複合成肽 (COP)
  • 舌下含片免疫療法
  • SLIT片劑製劑 (舌下免疫療法片劑製劑)
  • 佐劑的潛在的作用
  • 已經過核准SLIT片劑產品
  • 美國
  • 歐洲
  • 處於開發階段的舌下過敏片劑
  • Birch
  • Dust Mite
  • Grass
  • Ragweed
  • 市場資料、預測
  • 市場要素
  • 法規要素、課題
  • 美國
  • 歐洲
  • 日本
  • 參加試驗的患者轉移到相關處方型行銷
  • 對OTC鼻炎治療產品的市場衝擊
  • 臨床實驗及藥物研發
  • 管理護理、醫療經濟
  • 企業簡介
Product Code: SLT397K

Immunotherapy involves the administration of gradually increasing doses of the allergen over a period of time to desensitize the patient. It is the only known treatment that modifies the immune response and treats the cause rather than the symptoms. In the United States, the only licensed route of administration is subcutaneous injection (SCIT). An alternative to SCIT is sublingual immunotherapy (SLIT). The medication is kept beneath the tongue where it is absorbed into the mucosa. Though complex and not fully characterized mechanisms, administration of allergens through the oral, gingival, or sublingual mucosa can decrease the allergic response thus desensitizing the patient by modifying disease at least temporarily if not permanently (i.e. inducing tolerance). The incidence of severe or serious AE associated with SLIT is significantly lower than with SCIT such that SLIT which may be self-administered at home, while safe use of SCIT requires administration in a clinic that is capable of responding to systemic allergic reactions.

What You Will Learn

  • What approved allergy immunotherapeutics (AIT) are currently marketed, how are they administered, what are the device specifics, and who markets them?
  • Who are the important AIT suppliers, their manufacturing infrastructure and locations, their capabilities?
  • What are the major factors driving demand for self-administered AIT products including SLIT tablets?
  • How important are manufacturer relationships and what are the key alliances in the industry?
  • What are the essential factors, issues, technologies and market development issues for self-administered AIT products?
  • What are the significant economic, technology, and regulatory factors affecting AIT products?

Table of Contents

  • Executive Summary
  • Allergy Immunotherapy Market Dynamics
  • Competitive Landscape
  • The Market for Allergy Immunotherapy
  • Allergen Market Segments
  • Pollen-based Allergies
  • Possible Effects of Air Pollution in Allergic Diseases
  • Dust Mites
  • Pet Allergies
  • Food Allergies
  • Therapeutic Market Segments
  • Named Patient Products
  • Prescription Products
  • Emerging Therapeutic Segments
  • Synthetic Peptide Epitopes
  • Intralymphatic (ILIT) Administration
  • Epicutaneous Administration
  • Next Generation AIT
  • Recombinant Allergens
  • Allergy Therapeutics Technology Platforms
  • Contiguous Overlapping Peptides (Anergis)
  • Sublingual Tablet Immunotherapy
  • SLIT Tablet Formulations
  • The Potential Role of Adjuvants
  • Approved SLIT Tablet Products
  • U.S.
  • Europe
  • Development-stage Sublingual Allergen Tablets
  • Birch
  • Dust Mite
  • Grass
  • Ragweed
  • Market Data and Forecasts
  • Market Factors
  • Regulatory Factors and Issues
  • United States
  • Europe
  • Japan
  • The Shift from Named Patient to Prescription-based Marketing
  • The Market Impact on OTC Rhinitis Treatment Products
  • Clinical Trials and Product Development
  • Managed Care & Healthcare Economics
  • Company Profiles
Back to Top